Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Bevacizumab with or without Irinotecan in Metastatic Colorectal Cancer
NCT01249638Phase 3Unknown
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Dec 2010
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan in colorectal cancer (metastatic) (mCRC), sponsored by Ludwig Maximilian University of Munich. Status: unknown.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01249638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01249638.